This characteristic makes SST0116CL1 a potentially superior Hsp90 inhibitor in the situation where P-gp is expressed, enabling it, to overcome the MDR barrier that commonly undermines cancer therapy. This evidence concerns the gene HSP90AA1 and cancer.